Actinium to present ATNM-400 data at SNMMI 2026; receives NYSE American listing notice

Actinium Pharmaceuticals announced it will present updates on its ATNM-400 Actinium-225 antibody radioconjugate program across three presentations at the SNMMI 2026 conference, showcasing data in prostate cancer and NSCLC. The company also received a notice of non-compliance with NYSE American continued listing standards under Section 1003(a)(ii).